secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001437749-25-025762
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources
--------------------------------------------------------------------------------

- Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.
- Decision driven by limited resources and desire to advance istaroxime into broader acute heart failure.
- No safety concerns were cited as the reason for termination.
- CEO Jed Latkin confirmed the termination in the 8-K filing filed August 8, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/0001437749-25-025762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/wint20250808_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer